| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_066828a4b6f7a816447cb8ba1bcbb40e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-974 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6429
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6424 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 |
| filingDate |
1996-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70ea23da23616034046c70fe5f218b27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c668f4cc1e3bbe92a53f8ddb85d03047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ec0861aa1f5fed95c62a2dd76d8e09b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14ec16aad101c684fcd4e58dd4a5abcf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51f93030b9a21a2068bfb16a9935abb9 |
| publicationDate |
1998-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CZ-402097-A3 |
| titleOfInvention |
Prothrombin derivatives |
| abstract |
The invention relates to novel prothrombin mutants or derivatives thereof having one or more changes in the protein sequence as against the natural protein, are either inactive or have an activity of 10 % at the most and preferably no more than 0.25 % of the natural protein and have a bonding capacity to natural ligands (natural or artificial anticoagulants) essentially corresponding to that of the natural protein. The description also relates to the use of mutated prothrombin mutants or derivatives as pharmaceutical preparations. |
| priorityDate |
1995-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |